Pediatrics

As research and clinical experience continue, Hemangeol's role in the management of infantile hemangioma is likely to expand, further improving the lives of affected children.

With some of the most effective antidepressants containing a black box warning, safe and effective treatment for young adults is hard to come by.

Children born at 24- through 34-weeks’ gestation could have neurobehavioral problems and developmental dysfunctions, including language, executive function, attention, and behavioral disorders.

In this episode, we spoke with an expert about the potential impacts of new guidelines on adolescents, as well as the risks associated with new anti-obesity drugs.

Pediatric and maternal respiratory syncytial virus (RSV) vaccines are being studied to reduce the burden of RSV, and more research is needed to understand whether this can reduce wheeze and asthma.

Cases of certain HPV-related high-grade disease were not found in the 10-year follow up for girls and boys who received 3 doses of the Gardasil 9 injection.

The upcoming study seeks to analyze whether immature lungs in infants infected with respiratory syncytial virus increases the likelihood of developing asthma later in life.

The fixed-dose abacavir/dolutegravir/lamivudine combination is indicated for the once-daily treatment of children weighing at least 6 kg to <25 kg with HIV-1 infection.

Pharmacists can play a crucial role in educating parents and helping remind them about the childhood vaccine schedule, which can be quite complex.

Despite the limited data, prior research indicates there are no serious cannabis-related adverse effects in pediatric patients.

Nirsevimab (Beyfortus) is the first respiratory syncytial virus (RSV) preventative drug to be approved by the FDA, and can protect infants through their first RSV season for up to 5 months.

It is the first vaccine of its kind to be FDA approved, and it met multiple safety and efficacy standards through clinical trials.

The results differ from previous studies and the predictions of the researchers that the Child Tax Credit would reduce the prevalence of low birth weight among pregnant women across the country.

Guidelines from the American Academy of Pediatrics recommend treating obesity as a chronic illness.

The findings of the study demonstrate the need for preventive interventions for all infants in order to reduce the burden of severe illness from respiratory syncytial virus lower respiratory tract infections.

Key study finding shows associations between the beat frequency in the rhythmic stimulus in the frontal left sites of infant brains and pathways related to brain modulation and nucleotide levels.

Prior to this study, anti-platelet factor 4 disorder was thought to be caused by exposure to heparin or autoimmune conditions.

Many studies with a stated goal of advancing child health care in administratively-defined minors have no clinical value and may even harm young patients.

Approximately 57% of individuals who were shown a flowchart of the FDA vaccine approval process were very or somewhat likely to recommend a respiratory syncytial virus vaccine to a pregnant family member or friend compared to only 40% of those who were not shown the process.

After repeated treatment with packed red blood cell transfusions, treatment with intravenous immunoglobulin in a child with parvovirus B19 infection successfully resolved the infection and negated the need for further transfusions.

A bit of preparation can set children up for success and reduce the stress of this busy time.

Updated guidelines, comprehensive review, and an investment of resources into pediatric preventive cardiology programs could help provide successful care.

CDC Advisory Committee on Immunization Practices voted 10 to 0 to recommend the routine use of nirsevimab-alip (Beyfortus; Sanofi and AstraZeneca) for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants.

The approval marks the first monoclonal antibody approved to protect all infants through their first respiratory syncytial virus season.

The phase 3 S1826 trial is the largest Hodgkin lymphoma study in NCTN history.